Certara, Inc. (CERT) Earnings Call Transcripts

Certara, Inc.'s Latest Earnings Call - June 3, 2026

In the Q1 2026 earnings call for Certara, Inc. (CERT:US), management outlined a strategic realignment aimed at enhancing growth opportunities through two key segments: Accelerating Clinical Evidence (ACE) and Model Informed Drug Development (MID3). The company reported a revenue growth of 7% in software, signaling a positive trajectory, while management maintained a focus on R&D investment at approximately 10-11% of sales. Certara's guidance for the year remains optimistic, with expectations for continued growth driven by regulatory support and enhanced client engagement strategies.

Reported metrics

Guidance from management

Certara maintains an optimistic outlook for the year, focusing on growth driven by regulatory support and enhanced client engagement strategies. The company is committed to keeping R&D investment stable while pursuing operational efficiencies.

What management said

And just to add on to we view it as an opportunity to unify some of our disparate operations. So we're able to take this as a chance to unify, which is also sort of the backbone of some of the operating metrics that we've been looking at that are going to help drive growth for the organization as we look toward the second half of this year.

Yes. That range is in the right spot because if you think about it, yes, we're putting investment there, but we're also finding efficiencies. We talked about AI can be used within our teams, not only within the R&D team, but in the finance team, the HR team, the IT team. So we do believe we can find some productivity using AI tools ourselves as a partial offset to some of the investment that we've been putting into t...

What analysts pressed on

Analysts expressed concerns regarding the execution challenges that led to softer services bookings in Q1. There were also questions about the effectiveness of the new sales alignment strategy and its impact on future growth.

Main topics on the call

• Strategic Realignment — Management announced a realignment into two segments, ACE and MID3, to better address client needs and accelerate growth. CEO Jon Resnick stated, "We’ve been very focused strategically on how we set ourselves up for broa...
• Revenue Growth in Software — Certara reported a 7% revenue growth in software for Q1 2026, exceeding expectations. This growth is attributed to improved sales strategies and a focus on new software sales as a key performance indicator.
• Cost Management Initiatives — The company aims to achieve $10 million in cost reductions while maintaining R&D investments. CFO John Gallagher noted, "We believe that we can make the investment in R&D and take that cost out mainly through some of the...
• AI Integration into Products — Management emphasized the importance of integrating AI capabilities into existing products and developing new AI-native offerings. CEO Jon Resnick mentioned, "We believe that there’s a range of options open to us and we’...

Read the full Certara, Inc. transcript (June 3, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 69 Certara, Inc. earnings call transcripts on record, spanning March 4, 2021 to June 3, 2026. Based on this history, Certara, Inc. reports quarterly. The most recent call on file is dated June 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CERT

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Technology

Calls on record

69

First call

March 4, 2021

Most recent

June 3, 2026

Reporting cadence

quarterly